Add like
Add dislike
Add to saved papers

Lipoma treatment with a subdermal Nd:YAG laser technique.

BACKGROUND: Lipoma is the most common benign mesenchymal tumor composed of mature fat cells. The standard treatment for lipoma is excision. Many treatments have been described in order to minimize the scars produced by surgical excision. The treatment of lipoma using a subdermal laser produces an effective disruption of fat cells and results in a small scar.

OBJECTIVE: To evaluate the efficacy of subcutaneous intralesional application of a pulsed Nd:YAG laser as an option for the treatment of lipoma.

METHODS: From January 2001 to November 2007, 20 patients (11 women and nine men) with lipomas were treated using a subdermal, pulsed, 1064-nm Nd:YAG laser. After laser treatment, the oily solution, the product of laser action, was removed with a 2-mm cannula using a negative pressure of 350 mmHg. Histology and cytology of the treated tissue were used to analyze the effects of the laser on the fat cells. Ultrasound was performed in some subjects before and after laser treatment.

RESULTS: Subdermal lipoma treatment using a 1064-nm Nd:YAG laser resulted in complete or almost complete removal of the tumor in 100% of patients. Four partial relapses were observed that were treated successfully by the same procedure. Adverse effects were mild and temporary. The combination of a 1064-nm Nd:YAG laser and removal of the cell debris by a suction cannula presented an effective therapeutic option for patients with lipoma.

CONCLUSIONS: The treatment of lipoma using a 1064-nm Nd:YAG laser is a minor invasive procedure which does not result in large scars. Laser treatment is an effective and safe option for cellular disruption.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.
Urinary Tract Infections: Core Curriculum 2024.American Journal of Kidney Diseases 2023 October 31

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app